Pfizer Sues Metsera and Novo Nordisk Over Breach of Merger Agreement
Pfizer files lawsuit against Metsera, its board, and Novo Nordisk for breaching a merger agreement, claiming illegal interference and regulatory risks in Novo Nordisk’s proposal.
/ 84 items
#NVO↓
Eli Lilly Soars on Blockbuster Weight-Loss Drug Sales, Raises 2025 Outlook
Eli Lilly beats Q3 earnings expectations with $17.6B revenue as Zepbound and Mounjaro drive growth. The Company raises full-year forecast amid booming weight-loss drug market.
Novo Nordisk Makes $9 Billion Bid for Metsera, Topping Pfizer's Offer
Novo Nordisk offers $77.75/share for Metsera in $9B deal, beating Pfizer's bid. Two-step structure includes immediate $56.50 dividend + milestone payments.
Novo Nordisk Challenges Pfizer's $4.9B Deal for Obesity Startup Metsera
Novo Nordisk makes higher bid for Metsera to outbid Pfizer's $4.9B deal. Learn why this obesity drug startup is sparking a bidding war between pharmaceutical giants.
Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results
Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.
Oral VTX3232 Study Reveals Significant Reductions in Inflammatory Cardiovascular Risk Markers
Ventyx Biosciences' VTX3232 demonstrates significant reduction in heart disease risk markers in Phase 2 trial, with strong anti-inflammatory effects and good safety profile.